Samsung Biologics Acquires First U.S. Manufacturing Site for $280 Million
Samsung Biologics America (SBA), the U.S. subsidiary of South Korea-based Samsung Biologics, has entered into an agreement with GSK to acquire 100% of Human Genome Sciences, a biomanufacturing facility located in Rockville, Maryland. The acquisition is valued at $280 million.
This strategic move marks a significant expansion of Samsung Biologics’ global footprint and underscores its long-term commitment to the U.S. market. The transaction establishes the company’s first manufacturing site on American soil.
The Rockville facility includes two cGMP (Current Good Manufacturing Practice) plants. Samsung Biologics plans to retain approximately 500 employees currently working at the site. Additionally, the company intends to invest further in expanding capacity and upgrading technology at the facility.
“This landmark acquisition is a testament to our unwavering commitment to advancing global healthcare and bolstering our manufacturing capabilities in the U.S.,” said John Rim, CEO and President of Samsung Biologics. “The investment will enable us to deepen our collaboration with federal, state, and local stakeholders to best serve our customers and partners while ensuring a reliable and stable supply of life-saving therapeutics.”
The acquisition reflects Samsung Biologics’ ongoing efforts to enhance its global manufacturing network and support a broader range of biopharmaceutical customers across key regions.
